Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Glaucoma Research Foundation (GRF)

Glaucoma Research Foundation (GRF)

Glaucoma Research Foundation is a national non-profit organization dedicated to finding a cure for glaucoma. Founded in 1978 in San Francisco, we fund glaucoma research world-wide.

The Glaucoma 360 the New Horizons Forum unites key clinical, industry, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment. Presented by the Glaucoma Research Foundation, this annual catalyst meeting is designed to bring the essential components together in order to speed the translation of new ideas into clinical practice.

Further Resources

Close Popup